Alexion Pharmaceuticals (ALXN)
Alexion Pharmaceuticals Revenue Growth: 47.32%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ALXN Revenue Growth Rankings
| Overall | 91st percentile | 371 of 4358 |
| Sector | 84th percentile | 69 of 456 in Healthcare |
| Industry | 71st percentile | 36 of 126 in Biotechnology |
ALXN Revenue Growth Range, Past 5 Years
| Minimum | 34.15% | Sep 2009 |
| Maximum | 17910% | Dec 2007 |
| Average | 1555% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ALXN related companies
ALXN News
B/O watch over 95. Give it a bit of time to set up. $ALXN http://chart.ly/x9st6fr
about 19 hours ago by 1nvestor
about 19 hours ago by 1nvestor
$ALXN http://stks.co/3yyU ALXN is ready for a breakout, buy area is above $95
about 3 days ago by SMCHARTcom
about 3 days ago by SMCHARTcom
The weekly volume bar on $ALXN is a beauty. One of the best charts. Fundamental story strong as well
about 3 days ago by cubbiebears
about 3 days ago by cubbiebears
is the volume in $alxn simply attributed towards funds mirroring spy needing to buy?
about 3 days ago by rohitjenveja
about 3 days ago by rohitjenveja
@Momb $QCOR has been on my radar for quite some time, I will however keep an eye on $ALXN and $ARMH... :) thank you....
about 3 days ago by jfrankiep
about 3 days ago by jfrankiep
@harmongreg I've added an "Exemption" feature for stocks that don't meet all criteria but look promising for the Roll. $ALXN $BCR $CL $TSCO
about 4 days ago by 1nvestor
about 4 days ago by 1nvestor
$ALXN giving up the momentum it got from being added to the S&P 500. However, it is holding the 50-day line so far. $SPY
about 4 days ago by DarvasTrader
about 4 days ago by DarvasTrader
$ALXN In todays market, if your stock rises 5%, take the gain and run.
about 4 days ago by mmdongare
about 4 days ago by mmdongare
$ALXN up big this morning on news that it was joining the S&P 500. But fades as the day goes on. Churning. $SPY $SPX
about 5 days ago by DarvasTrader
about 5 days ago by DarvasTrader
Polo Ralph Lauren, Best Buy Included in Stocks Up on High Volume Tuesday
May 22, 12:33PM Fox Business
May 22, 12:33PM Fox Business
$ALXN nibbled a few shares @93.88. This stock was good to me before the correction.
about 5 days ago by ssmith98
about 5 days ago by ssmith98
$ALXN http://stks.co/3w7s Worth eyeing - poised to breakout to new highs
about 5 days ago by TraderFlorida
about 5 days ago by TraderFlorida
Pre-Open Movers 5/22: (EDGR) (BNHN) (RL) Higher; (EXPR) (FB0 (AZO) Lower (more...)
May 22, 9:31AM Street Insider
May 22, 9:31AM Street Insider
Alexion to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 10:00AM Business Wire
May 10, 10:00AM Business Wire
Alexion to Present at Deutsche Bank Securities 37th Annual Health Care Conference
Apr 30, 10:00AM Business Wire
Apr 30, 10:00AM Business Wire
Oppenheimer updates 2012-2015 EPS Estimates on Alexion Pharmaceuticals (ALXN)
Apr 25, 2:13PM Street Insider
Apr 25, 2:13PM Street Insider
Barclays Maintains an 'Overweight' on Alexion Pharmaceuticals (ALXN); Raising PT to $104
Apr 25, 1:52PM Street Insider
Apr 25, 1:52PM Street Insider
UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Alexion Pharmaceuticals
Apr 25, 11:16AM Benzinga
Apr 25, 11:16AM Benzinga
Canaccord Genuity Maintains a 'Buy' on Alexion Pharmaceuticals (ALXN); Raising PT and Estimates on Beat & Raise
Apr 25, 9:48AM Street Insider
Apr 25, 9:48AM Street Insider
UPDATE: Jefferies Raises PT to $76 on Alexion Pharmaceuticals; Maintains Hold on Lofty Valuation
Apr 25, 9:24AM Benzinga
Apr 25, 9:24AM Benzinga
Alexion Pharmaceuticals (ALXN) High Valuation: Jefferies Says Hold, Ups Price Target
Apr 25, 9:03AM Street Insider
Apr 25, 9:03AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALXN | 92.42 | -0.68 | -0.73% | 17.19B |
| ALX | 391.06 | +0.06 | +0.02% | 1.998B |
| ALVR | 0.49 | +0.03 | +6.52% | 28.41M |
| AMNB | 22.00 | -0.24 | -1.08% | 172.26M |
| AMLP | 15.95 | +0.05 | +0.31% | |
| AMLN | 27.96 | +2.16 | +8.37% | 4.496B |
| AMKR | 4.65 | +0.07 | +1.53% | 782.83M |
| AMJ | 37.36 | +0.23 | +0.62% | |
| AMIC | 4.35 | -0.34 | -7.25% | 35.97M |
| AMGN | 69.05 | -0.05 | -0.07% | 54.16B |
